# US 2012/0252830 A1 · Substituted Aminobutyric Derivatives as Neprilysin Inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252830 A1
- Document ID: US20120252830A1
- Status: Published application
- Kind: A1
- Application number: 13/490,562
- Filed: 2012-06-07
- Published: 2012-10-04
- Earliest claimed: 2009-05-28
- Assignees: Novartis AG
- Inventors: Gary Mark Coppola; Yuki Iwaki; Rajeshri Ganesh Karki; Toshio Kawanami; Gary Michael Ksander; Muneto Mogi; Robert Sun
- Web page: https://patentgrep.com/patent/US20120252830A1

## CPC

- A61K 31/194: having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/10: Antioedematous agents; Diuretics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/06: Antiarrhythmics
- A61P 9/08: Vasodilators for multiple indications
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 11/06: Antiasthmatics
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/04: for inducing labour or abortion; Uterotonics
- A61P 15/06: Antiabortive agents; Labour repressants
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 27/16: Otologicals
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/02: Local antiseptics
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C 233/47: having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
- C07C 233/63: having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C 233/87: of a carbon skeleton containing six-membered aromatic rings
- C07C 235/52: having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C 235/74: of a saturated carbon skeleton
- C07C 235/82: with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
- C07C 251/12: being acyclic
- C07C 257/06: having carbon atoms of imino-carboxyl groups bound to hydrogen atoms, to acyclic carbon atoms, or to carbon atoms of rings other than six-membered aromatic rings
- C07C 271/12: to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C 275/16: being further substituted by carboxyl groups
- C07C 311/19: to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C 317/44: having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07D 207/34: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 209/18: Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 213/56: Amides
- C07D 213/81: Amides; Imides
- C07D 213/82: in position 3
- C07D 231/14: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D 239/28: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D 261/18: Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
- C07D 271/10: 1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D 277/64: with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
- C07D 285/12: 1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D 303/48: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms, e.g. ester or nitrile radicals
- C07D 307/68: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 309/40: Oxygen atoms attached in positions 3 and 4, e.g. maltol
- C07D 333/24: Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 333/40: Thiophene-2-carboxylic acid
- C07C 2601/02: with a three-membered ring
- C07C 2601/04: with a four-membered ring
- C07C 2601/14: The ring being saturated
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The present invention provides a compound of formula I′; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, X and n are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

## Claims

### Claim 1

A compound of the formula (I′):
or a pharmaceutically acceptable salt thereof, wherein:
R1 is C1-7alkyl;
for each occurrence, R2 is independently C1-7alkyl, NO2, CN, halo, C3-7cycloalkyl, hydroxy, C1-7alkoxy, halo-C1-7alkyl, NRbRc, C6-10aryl, heteroaryl or heterocyclyl; wherein Rb and Rc for each occurrence, are independently H or C1-7alkyl;
R3 is A1C(O)X1;
R5 is H, halo, hydroxy, C1-7alkoxy, halo, C1-7alkyl or halo-C1-7alkyl; and
X and X1 are independently OH, —O—C1-7alkyl, —NRbRc, —NHS(O)2—C1-7alkyl, —NHS(O)2-benzyl or —O—C6-10aryl; wherein alkyl is optionally substituted with one or more substituents independently selected from the group consisting of aryl, heteroaryl, heterocyclyl, —C(O)NH2, —C(O)NH—C1-6alkyl, and —C(O)N(C1-6alkyl)2;
A1 is a bond or a linear C1-4alkylene substituted with one or more substituents independently selected from the group consisting of halo, O-acetate, C1-7 alkyl and C3-7cycloalkyl; in which two geminal alkyl can optionally combine to form a C3-7cycloalkyl; or
A1 is a linear or branched C2-6alkenylene; or
A1 is a linear C1-4 alkylene wherein one or more carbon atom(s) is/are replaced with an heteroatom selected from O, NRa; and A1 is optionally substituted with one or more substituents independently selected from the group consisting of halo and C1-7alkyl; in which Ra for each occurrence, is independently H, C1-7alkyl or CH2C(O)OH; or
A′ is a C3-7cycloalkyl, a heterocyclyl, a phenyl or a heteroaryl in which phenyl and heteroaryl are optionally substituted with one or more substituents independently selected from the group consisting of C1-7alkyl, C3-7cycloalkyl, halo-C1-7alkyl, hydroxy, C1-7alkoxy, halo, NRbRc, OCH2CO2H, and OCH2C(O)NH2; or
A1 is —C1-4alkylene-C6-10-aryl-, —C1-4alkylene-heteroaryl- or —C1-4alkylene-heterocyclyl-, wherein A1 may be in either direction; and
n is 0, 1, 2, 3, 4 or 5;
wherein each heteroaryl is a monocyclic or bicyclic aromatic ring comprising 5-10 ring atoms selected from carbon atoms and 1 to 5 heteroatoms, and
each heterocyclyl is a monocyclic saturated or partially saturated but non-aromatic moiety comprising 4-7 ring atoms selected from carbon atoms and 1-5 heteroatoms, wherein each heteroatom of a heteroaryl or a heterocyclyl is independently selected from O, N and S.

### Claim 2 (depends on 1)

A compound of formula (I) according to claim 1:
or a pharmaceutically acceptable salt thereof, wherein:
R1 is C1-7alkyl;
for each occurrence, R2 is independently C1-7alkyl, NO2, CN, halo, C3-7cycloalkyl, hydroxy, C1-7alkoxy, halo-C1-7alkyl, NRbRc, C6-10aryl, heteroaryl or heterocyclyl; wherein Rb and Rc for each occurrence are independently H or C1-7alkyl;
R3 is A1C(O)X1;
R5 is H, halo, hydroxy, C1-7alkoxy, halo, C1-7alkyl or halo-C1-7alkyl; and
X and X1 are independently OH, —O—C1-7alkyl or NRbRc, —O—C6-10aryl; wherein alkyl is optionally substituted with one or more substituents independently selected from the group consisting of aryl, heteroaryl, heterocyclyl, C(O)NH2, C(O)NH—C1-6alkyl, and C(O)N(C1-6alkyl)2;
A1 is a bond or a linear C1-4alkylene substituted with one or more substituents independently selected from the group consisting of halo, O-acetate, C1-7 alkyl and C3-7cycloalkyl; in which two geminal alkyl can optionally combine to form a C3-7cycloalkyl; or
A1 is a linear C1-4 alkylene wherein one or more carbon atom(s) is/are replaced with an heteroatom selected from O, NRa; wherein A1 is optionally substituted with one or more substituents independently selected from the group consisting of halo and C1-7alkyl; in which Ra for each occurrence is independently H, C1-7alkyl or CH2C(O)OH; or
A1 is a C3-7cycloalkyl, a heterocyclyl, a phenyl or a heteroaryl in which phenyl and heteroaryl are optionally substituted with one or more substituents independently selected from the group consisting of C1-7alkyl, C3-7cycloalkyl, halo-C1-7alkyl, hydroxy, C1-7alkoxy, halo, NRbRc, OCH2CO2H, and OCH2C(O)NH2; or
A1 is —C1-4alkylene-C6-10-aryl-, —C1-4alkylene-heteroaryl- or —C1-4alkylene-heterocyclyl-, wherein A1 may be in either direction; and
n is 0, 1, 2, 3, 4 or 5;
wherein each heteroaryl is a monocyclic or bicyclic aromatic ring comprising 5-10 ring atoms selected from carbon atoms and 1 to 5 heteroatoms, and
each heterocyclyl is a monocyclic saturated or partially saturated but non-aromatic moiety comprising 4-7 ring atoms selected from carbon atoms and 1-5 heteroatoms, wherein each heteroatom of a heteroaryl or a heterocyclyl is independently selected from O, N and S.

### Claim 3 (depends on 1)

The compound of claim 1 wherein:
R1 is C1-7alkyl;
for each occurrence, R2 is independently C1-7alkyl, halo, C3-7cycloalkyl, hydroxy, C1-7alkoxy, halo-C1-7alkyl, NRbRc, C6-10aryl, heteroaryl or heterocyclyl; wherein Rb and Rc, for each occurrence, are independently H or C1-7alkyl;
R3 is A1C(O)X1;
R5 is H; and
X and X1 are independently OH, —O—C1-7alkyl or NRbRc;
A1 is a linear C1-4 alkylene substituted with one or more substituents independently selected from the group consisting of halo, O-acetate, C1-7 alkyl and C3-7cycloalkyl; in which two geminal alkyl can optionally combine to form a C3-7cycloalkyl; or
A1 is a linear C1-4 alkylene wherein one or more carbon atom(s) is/are replaced with an heteroatom selected from O, NRa; wherein A1 is optionally substituted with one or more substituents independently selected from the group consisting of halo and C1-7alkyl; in which Ra for each occurrence, is independently H, C1-7alkyl or CH2C(O)OH; or
A1 is a C3-7cycloalkyl, a heterocyclyl, a phenyl or a heteroaryl in which phenyl and heteroaryl are optionally substituted with one or more substituents independently selected from the group consisting of C1-7alkyl, C3-7cycloalkyl, halo-C1-7alkyl, hydroxy, C1-7alkoxy, halo, NRbRC, OCH2CO2H, and OCH2C(O)NH2; and
n is 0, 1, 2, 3, 4 or 5;
wherein each heteroaryl is a monocyclic or bicyclic aromatic ring comprising 5-10 ring atoms selected from carbon atoms and 1 to 5 heteroatoms, and
each heterocyclyl is a monocyclic saturated or partially saturated but non-aromatic moiety comprising 4-7 ring atoms selected from carbon atoms and 1-5 heteroatoms, wherein each heteroatom of a heteroaryl or heterocyclyl is independently selected from O, N and S; or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

The compound according to claim 1, having Formulae II or IIA:
or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

The compound according to claim 1 having Formulae III or IIIA:
wherein Y1, Y2 and Y3 are independently N, NH, S, O or CH; or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1)

The compound according to claim 1 having Formulae IV or IVA:
wherein each Y4 is independently N, S, O or CH; or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1)

The compound according to claim 1 having Formulae V or VA:
wherein W1, W2, W3 and W4 are independently N, or CRe, in which each Re is independently selected from H, C1-7alkyl, C3-7cycloalkyl, halo-C1-7alkyl, hydroxy, C1-7alkoxy, halo, NRbRc, OCH2CO2H and OCH2C(O)NH2; or a pharmaceutically acceptable salt thereof.

### Claim at position 8

8-9. (canceled)

### Claim 10 (depends on 1)

The compound of claim 1 wherein R1 is methyl, R2 is independently halo, C1-7alkyl, halo-C1-7alkyl, hydroxy and C1-7alkoxy, n is 0, 1 or 2 and X and X1 are independently OH or —O—C1-7alkyl; or a pharmaceutically acceptable salt thereof.

### Claim 11 (depends on 1)

The compound of claim 1 wherein n is 1 or 2; R2 is meta-chloro and the other optional R2 group is halo, C1-7alkyl, halo-C1-7alkyl, hydroxy and C1-7alkoxy; or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.

### Claim 13 (depends on 1)

A combination comprising: a compound according to claim 1 or a pharmaceutically acceptable salt thereof, and one or more therapeutically active agents selected from HMG-Co-A reductase inhibitor, an anigiotensin receptor blocker, angiotensin converting enzyme Inhibitor, a calcium channel blocker, an endothelin antagonist, a renin inhibitor, a diuretic, an ApoA-I mimic, an anti-diabetic agent, an obesity-reducing agent, an aldosterone receptor blocker, an endothelin receptor blocker, an aldosterone synthase inhibitors, a CETP inhibitor and a phosphodiesterase of type 5 (PDE5) inhibitor.

### Claim 14 (depends on 1)

A method of inhibiting neutral endopeptidase EC. 3.4. 24.11. activity in a subject in need thereof, comprising: administering to the subject a therapeutically effective amount of the compound according to claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 1, 4, 9, 21, 22)

A method of treating a disorder or a disease associated with neutral endopeptidase EC. 3.4. 24.11. activity in a subject in need thereof, comprising: administering to the subject a therapeutically effective amount of the compound according to any one of claims 1, 4, 9, 21 or 22 or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 15)

The method according to claim 15, wherein the disorder or the disease is selected from hypertension, pulmonary hypertension, isolated systolic hypertension, resistant hypertension, peripheral vascular disease, heart failure, congestive heart failure, left ventricular hypertrophy, angina, renal insufficiency, renal failure, diabetic nephropathy, non-diabetic nephropathy, nephroic syndrome, glomerulonephritis, scleroderma, glomerular sclerosis, proteinurea of primary renal disease, renal vascular hypertention, diabetic retinopathy and end-stage renal disease (ESRD), endothelial dysfunction, diastolic dysfunction, hypertrophic cardiomyopathy, diabetic cardiac myopathy, supraventricular and ventricular arrhythmias, atrial fibrillation (AF), cardiac fibrosis, atrial flutter, detrimental vascular remodeling, plaque stabilization, myocardial infarction (MI), renal fibrosis, polycystic kidney disease (PKD), Pulmonary Arterial hypertension, renal failure, cyclical oedema, Meniéres disease, hyperaldosteroneism hypercalciuria, ascites, glaucoma, menstrual disorders, preterm labour, pre-eclampsia, endometriosis, reproductive disorders, asthma, obstructive sleep apnea, inflammation, leukemia, pain, epilepsy, affective disorders, depression and psychotic condition, dementia, geriatric confusion, obesity and gastrointestinal disorders, wound healing, septic shock, gastric acid secretion dysfunction, hyperreninaemia, cystic fibrosis, restenosis, type-2 diabetes, metabolic syndrome, diabetic complications, atherosclerosis, male and female sexual dysfunction.

### Claim at position 16

17-19. (canceled)

### Claim 20 (depends on 4)

The compound of claim 4 wherein n is 1 or 2; R2 is meta-chloro and the other optional R2 group is halo, C1-7alkyl, halo-C1-7alkyl, hydroxy and C1-7alkoxy; or a pharmaceutically acceptable salt thereof.
